Business Wire

Boehringer Ingelheim Exercises Option on Second Hepatic Disease Target From Research Collaboration with Dicerna

Share

Boehringer Ingelheim and Dicerna Pharmaceuticals (NASDAQ: DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that Boehringer Ingelheim has exercised an option to receive exclusive rights to a second hepatic disease target emerging from its research collaboration and license agreement with Dicerna. The collaboration, established in October 2017, aims to discover and develop novel GalXC™ RNAi therapeutics for the treatment of chronic liver diseases, with an initial focus on nonalcoholic steatohepatitis (NASH), a devastating disease for which there is no approved treatment.

The option is the second target under the two companies’ research collaboration and license agreement. Under the terms of the agreement, Boehringer Ingelheim will be responsible for future clinical development and commercialization of the therapeutic target. Dicerna is eligible to receive development and commercial milestone payments, and royalties on worldwide net sales.

“It is extremely gratifying for Boehringer Ingelheim to exercise its option for a second therapeutic candidate from our productive research collaboration,” said Douglas M. Fambrough, President and Chief Executive Officer of Dicerna. “The option exercise underscores the potential of Dicerna’s GalXC technology platform in facilitating the discovery and development of novel RNAi therapies for nonalcoholic steatohepatitis and other chronic liver diseases. We look forward to continued progress and the potential advancement of clinical candidates from our partnership.”

Dicerna and Boehringer Ingelheim selected the target based on its ability to be drugged using Dicerna’s proprietary GalXC technology platform. The GalXC platform uses RNAi to inhibit the expression of disease-causing genes by destroying the messenger RNAs (mRNAs) of those genes. The approach has the potential to treat diseases by silencing previously inaccessible drug targets.

“Boehringer Ingelheim is pleased with the progress of our initial collaboration with Dicerna and based on early findings and our strong relationship, we are expanding our research efforts,” said Clive R. Wood, Ph.D., Corporate Senior Vice President Discovery Research at Boehringer Ingelheim. “Today’s announcement exemplifies our commitment to discovering new therapies for NASH and other chronic liver diseases and advances our research efforts in this priority area.”

NASH is caused by the buildup of fat in the liver, potentially leading to liver fibrosis and cirrhosis. It has an especially high prevalence among obese and diabetic patients and is an area of high unmet medical need. NASH is expected to soon become the most common cause of advanced liver disorders, and it often necessitates liver transplantation.

Dicerna is building a portfolio of research and development programs to advance the treatment of diseases involving the liver, including chronic liver diseases, viral infectious diseases, cardiovascular diseases and rare diseases. The company aims to leverage its proprietary GalXC technology to develop innovative RNAi therapeutics to positively transform the lives of individuals living with these diseases.

Cautionary Note on Forward-Looking Statements

This press release includes forward-looking statements. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Examples of forward-looking statements include, among others, statements Dicerna makes regarding: (i) the therapeutic and commercial potential of GalXC™; (ii) research and development plans related to GalXC; and (iii) the potential of our technology and drug candidates in our research and development pipeline. The process by which an early stage platform such as GalXC could potentially lead to an approved product is long and subject to highly significant risks, particularly with respect to a pre-clinical research collaboration. Applicable risks and uncertainties include those relating to Dicerna’s preclinical research and other risks identified under the heading "Risk Factors" included in Dicerna’s most recent Form 10-Q filing and in other future filings with the SEC. The forward-looking statements contained in this press release reflect Dicerna's current views with respect to future events, and Dicerna does not undertake and specifically disclaims any obligation to update any forward-looking statements.

Please click on the link for ‘Notes to Editors’ and ‘References’:
http://www.boehringer-ingelheim.com/press-release/second-dicerna-hepatic-disease-target-option-exercise

Contact information

Contacts for Boehringer Ingelheim:
Dr. Reinhard Malin
Head of Communications Innovation Unit
Boehringer Ingelheim Corporate Center GmbH
Media + PR
press@boehringer-ingelheim.com
P: +49 6132 77-90815: M: + 49 151 150 20 690
www.boehringer-ingelheim.com

Linda Ruckel
Associate Director, Media and Corporate Reputation
Boehringer Ingelheim Pharmaceuticals, Inc.
Ridgefield, Connecticut
linda.ruckel@boehringer-ingelheim.com
P: 203-791-6672 :: C: 917-692-0848
www.boehringer-ingelheim.com

Contacts for Dicerna Pharmaceuticals:
Paula Schwartz
Managing Director
Rx Communications Group
pschwartz@rxir.com
P: 917-322-2216
www.rxir.com

Alex Van Rees
Senior Account Director
SmithSolve Communications
alex.vanrees@smithsolve.com
P: 973-442-1555 ext. 111
www.smithsolve.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

HSEVEN Accelerate World-Class African Startups16.7.2019 01:00:00 CESTPress release

HSEVEN, Africa’s largest accelerator is launching “HSEVEN DISRUPT AFRICA”, an ambitious startup acceleration program designed for entrepreneurs of the Moroccan and African diaspora. The 6-month program will provide a seed investment of €150,000 plus an eventual investment of €500,000 to €1.5 million. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190715005770/en/ HSEVEN team (Photo: AETOSWire) HSEVEN DISRUPT AFRICA is designed to support exceptional entrepreneurs building high-impact startups, and targets seed and early stage startups with 2 to 5 founders that are eager to impact Africa through innovative services, products and business models. The program will start with a global call for applications, followed by an international selection roadshow in New York, Montréal, San Francisco, Shanghai, Dubaï, Londres, Amsterdam, Paris, Casablanca. The selected startups will benefit from a seed investment of €150,000 at the beginn

PayPal Expands its International Money Transfer Service Xoom to 32 Markets across Europe15.7.2019 23:01:00 CESTPress release

Today, PayPal launched Xoom—its international money transfer service—in 32 markets1 across Europe. People in these markets can now use Xoom to quickly send money, pay bills or top up phones to more than 130 markets internationally. Xoom’s expansion to Europe is a significant milestone and another example of PayPal fulfilling its mission to make the movement and management of money more convenient, accessible, secure and affordable. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190715005823/en/ Xoom Launches in 32 Markets Across Europe (Photo: Business Wire) The global remittance market reached $689 billion in 2018, up from $633 billion in 2017 according to World Bank data2. In 2019, remittance flows to low- and middle-income countries are expected to reach $550 billion, to become their largest source of external financing. The global average cost of sending $200 remained high, at around 7 percent in the first quarter of 201

ResMed Inc. Completes $500M Private Placement Debt Offering15.7.2019 20:05:00 CESTPress release

ResMed Inc. (NYSE: RMD, ASX: RMD) announced today the successful pricing and closing of a private placement offering of $250,000,000 principal amount 3.24% senior notes due July 10, 2026, and $250,000,000 principal amount 3.45% senior notes due July 10, 2029. Net proceeds from the offering will be approximately $498 million, after deducting estimated fees and expenses related to the offering. The net proceeds will be used to pay down current borrowings on ResMed’s senior unsecured revolving credit facility. The notes are senior unsecured obligations of ResMed, and jointly and severally guaranteed by each Subsidiary Guarantor. “We are pleased to complete this U.S. private placement offering on attractive terms,” said Brett Sandercock, ResMed’s chief financial officer. “The transaction significantly lengthens our average debt maturity profile and provides improved visibility on our long-term funding costs.” This private placement offering is exempt from the registration requirements of t

SpeeDx Receives Clearance from Health Canada for ResistancePlus® MG Test15.7.2019 15:00:00 CESTPress release

SpeeDx Pty. Ltd. today announced Resistance Plus® MG has been cleared by Health Canada and is now available for sale across all Canadian provinces (not currently available in the U.S.). The molecular diagnostic test detects the sexually transmitted infection (STI) Mycoplasma genitalium, also known as Mgen, along with genetic markers linked to antibiotic resistance. This is the first commercially available test in Canada combining identification and therapeutic guidance information to support Resistance Guided Therapy for management of Mgen. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190715005544/en/ (Photo: Business Wire) Current Canadian management guidelines for Mgen direct laboratories to forward positive samples to the National Microbiology Laboratory for resistance testing.1 Now Canadian laboratories can utilize Resistance Plus MG and bring this service inhouse to generate more timely results for doctors and their p

Mouser Electronics Now Stocking Broad Portfolio of Xilinx Products15.7.2019 14:55:00 CESTPress release

Mouser Electronics, Inc. today announces a new global distribution agreement with Xilinx, Inc., the leader in adaptive and intelligent computing, to stock one of the industry’s broadest portfolios of Xilinx products, including digital downloads of development software and IP. Xilinx is the inventor of the FPGA, hardware programmable system-on-chips (SoCs) and the adaptive compute acceleration platform (ACAP), designed to deliver the most dynamic processor technology in the industry and enable the adaptable, intelligent and connected world of the future. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190715005546/en/ Mouser Electronics proudly announces a new global distribution agreement with Xilinx, Inc., the leader in adaptive and intelligent computing. Mouser will stock one of the industry’s broadest portfolios of Xilinx products. (Graphic: Business Wire) To learn more, visit www.mouser.com/xilinx. “Xilinx is an industry

Rimini Street Becomes Support Service Provider for Hyundai-Kia Motors’ Global Database Portfolio15.7.2019 13:00:00 CESTPress release

Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, the leading third-party support provider for Oracle and SAP software products and a Salesforce partner, today announced that it has been selected as the software support services provider to global auto manufacturer Hyundai-Kia Motors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190715005161/en/ Rimini Street announced that it has been selected as the software support services provider to global auto manufacturer Hyundai-Kia Motors. (Photo: Business Wire) By providing efficient, timely, and cost-effective database maintenance and support, Rimini Street plans to actively support Hyundai-Kia Motors in their endeavor to implement a business-driven IT roadmap. Cost Optimization and Desire for Quality Support To support response to paradigm shifts in the automobile industry and active technology innovation, Hyundai-Kia Motors se